On December 29, Alignment Healthcare insider Christopher Joyce reduced his holdings by selling 16,187 shares, representing a 5.0% decrease in his position. The transaction generated approximately $303,000 in proceeds and was disclosed in an SEC filing. After the sale, Joyce retained 307,699 shares, valued at roughly $5.77 million based on recent trading levels. This move follows other high-profile dispositions by senior executives and underscores a notable shift in insider sentiment.

Over December 29–30, four senior executives—including CEO John E. Kao and President Dawn Christine Maroney—disposed of nearly one million shares in combined transactions. Kao sold 605,648 shares for proceeds of about $11.35 million, while Maroney’s sale of 282,070 shares yielded roughly $5.29 million. Additional insiders (Robert L. Scavo and Hyong Kim) offloaded a further 82,235 shares. Collectively, these departures amount to over 20% reductions in individual holdings and may weigh on investor sentiment despite the company’s growth narrative.

In its latest quarter, Alignment Healthcare reported revenue of $993.7 million, up 43.5% year-over-year and surpassing consensus forecasts by nearly $13 million. The company delivered positive EPS of $0.02 against a year-ago loss of $0.14, though net margin remained slightly negative. With a debt-to-equity ratio near 2.0 and a current ratio of 1.61, financial leverage is elevated but manageable. Analysts are divided—eight hold Buy or Overweight ratings while three maintain Hold and one issues a Sell—resulting in a consensus Moderate Buy stance and a price target just above recent trading levels.